← Back to headlines
Teva and Medincell Receive FDA Review for Long-Acting Antipsychotic
Teva and Medincell have been granted FDA review for their long-acting antipsychotic drug, marking a step forward in its potential approval.
21 Feb, 14:09 — 21 Feb, 14:09
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
FDA Grants Breakthrough Status to Johnson & Johnson's Cancer Drug for Advanced Head and Neck Cancer
just now
Students Claim Covid Compensation from Universities
1h ago
Stroke Patients Under 45 in India Face High Mortality and Disability Rates
1h ago
The No. 1 Fruit for Longevity, According to a Healthy Aging Researcher
1h ago